Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
This trial is active, not recruiting.
|Treatment||rituximab, thalidomide, prednisone, etoposide, procarbazine, cyclophosphamide|
|Sponsor||Weill Medical College of Cornell University|
|Start date||November 2004|
|End date||December 2009|
|Trial size||46 participants|
|Trial identifier||NCT00151281, 047080073974|
Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide, and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle cell lymphoma. Specifically, response rate (RR) and time to disease progression (TTP) will be assessed.
1. Assess the toxicity profiles of RT-PEPC treatment in patients with relapsed mantle cell lymphoma.
2. Prospectively characterize the angiogenic profile of patients with mantle cell lymphoma during treatment with RT-PEPC. The dynamics of the angiogenic profile will be correlated with clinical response to RT-PEPC therapy.
3. Assess the quality of life of patients receiving RT-PEPC treatment
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
effect of drug combination on mantle cell lymphoma
time frame: duration of study
Male or female participants at least 18 years old.
- Histologically confirmed diagnosis of mantle cell Non-Hodgkin's Lymphoma with characteristic immunophenotypic profiles: CD5(+),CD23(-), CD19(+) or CD20(+), cyclin D1(+), and CD10(-)
- Patient has persistent / recurrent disease after standard chemotherapy
- Patient has not received either standard or investigational drugs within the last 3 weeks
- Available frozen tumor tissue obtained since completion of last prior therapy (rebiopsy if needed)
- Patient has measurable disease as defined by a tumor mass > 1.5 cm in one dimension
- Age > 18 years
- Absolute granulocyte count > 1000 cells/mm3
- Platelet count > 50,000 cells/mm3
- Creatinine < 2.0 x ULN
- Total bilirubin < 2.0 x ULN
- Patient has KPS > 50%
- Patient agrees to use birth control if of reproductive potential
- Known central nervous system (CNS) involvement by lymphoma
- Known HIV disease
- Known peripheral neuropathy > grade 2
- Patient is pregnant or nursing
- Patient has had major surgery within the last 3 weeks
- Patient is receiving other investigational drugs
|Official title||Phase II Trial of Anti-Angiogenic Therapy With RT-PEPC in Patients With Relapsed Mantle Cell Lymphoma|
|Principal investigator||John P Leonard, MD|
Call for more information